Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Tanabe Pharma America, Inc. Clear all
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

NCT04683848
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
MT-3921, Placebo
Biological
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Orange, California • Tallahassee, Florida • Augusta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 24, 2026, 7:36 PM EDT
Active, not recruiting Phase 3 Interventional

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05005975
View directory record Official record
Conditions
EPP, XLP
Interventions
MT-7117
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Huntington Beach, California • San Francisco, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

NCT04096950
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
MT-3921 Low dose
Biological
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Sacramento, California • Chicago, Illinois • Urbana, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

NCT03520036
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP)
Interventions
MT-7117 low dose, MT-7117 high dose, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

NCT03291067
View directory record Official record
Conditions
Menopause Hot Flashes
Interventions
MT-8554 1mg, MT-8554 5mg, MT-8554 10mg, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
63
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

NCT03541200
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
MT-8554
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
53
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 24, 2026, 7:36 PM EDT
Completed No phase listed Observational

Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)

NCT05276349
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Phoenix, Arizona • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

NCT04440592
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
MT-7117, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Glendale, Arizona • Los Angeles, California • Redwood City, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

NCT04793295
View directory record Official record
Conditions
Healthy Subjects
Interventions
MT-7117
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

NCT04116476
View directory record Official record
Conditions
Mild and Moderate Hepatic Impairment
Interventions
MT-7117
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

NCT03840993
View directory record Official record
Conditions
Endometrial Related Pain
Interventions
MT-2990, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
51
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

NCT04402489
View directory record Official record
Conditions
EPP, XLP
Interventions
Placebo, MT-7117 Low Dose, MT-7117 High Dose
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Huntington Beach, California • Miami, Florida • Brighton, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 24, 2026, 7:36 PM EDT
Not listed No phase listed Observational

Telespirometry in Amyotrophic Lateral Sclerosis (ALS)

NCT05106569
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Spirometry
Diagnostic Test
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Syracuse, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 24, 2026, 7:36 PM EDT
Recruiting No phase listed Observational

Analysis of Human ALS Tissues and Registry of ALS Patients

NCT05067179
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 24, 2026, 7:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

NCT05241535
View directory record Official record
Conditions
Healthy Subjects
Interventions
MT-7117, moxifloxacin, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 24, 2026, 7:36 PM EDT
Completed Phase 3 Interventional

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

NCT06144840
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Interventions
Dersimelagon, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Huntington Beach, California • San Francisco, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 24, 2026, 7:36 PM EDT